Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.
(2012) In Cancer Biotherapy & Radiopharmaceuticals 27(3). p.175-182- Abstract
- Metastatic disease after successful treatment of the primary tumor continues to be a therapeutic challenge. Enhancement of therapeutic effects by the administration of unlabeled monoclonal antibodies (mAbs) after radioimmunotherapy (RIT) may provide a means of preventing or delaying the development of metastatic disease. In the present study, Brown Norway rats with syngeneic grafted colon carcinomas were administered the minimal effective therapeutic dose of 400 MBq/kg lutetium-177 ((177)Lu)-DOTA-BR96. After 2 weeks, half of the animals were given 15 mg/kg unlabeled mAb BR96 as consolidation therapy. Treatment response and toxicity were monitored 100 days after the treatment with unlabeled BR96. The treatment with unlabeled mAb after RIT... (More)
- Metastatic disease after successful treatment of the primary tumor continues to be a therapeutic challenge. Enhancement of therapeutic effects by the administration of unlabeled monoclonal antibodies (mAbs) after radioimmunotherapy (RIT) may provide a means of preventing or delaying the development of metastatic disease. In the present study, Brown Norway rats with syngeneic grafted colon carcinomas were administered the minimal effective therapeutic dose of 400 MBq/kg lutetium-177 ((177)Lu)-DOTA-BR96. After 2 weeks, half of the animals were given 15 mg/kg unlabeled mAb BR96 as consolidation therapy. Treatment response and toxicity were monitored 100 days after the treatment with unlabeled BR96. The treatment with unlabeled mAb after RIT resulted in a complete response (CR) in 19 of 19 animals, while RIT alone resulted in a CR in 17 of 19 animals. The additional treatment did not affect the number of animals with metastatic disease or the time to clinical symptoms of metastases. RIT resulted in reversible myelotoxicity. The unlabeled mAb BR96 did not cause any additional toxicity, making it possible to repeat the consolidation therapy. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2431847
- author
- Eriksson, Sophie LU ; Ohlsson, Tomas G LU ; Nilsson, Rune LU and Tennvall, Jan
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- colon carcinoma, radioimmunotherapy, lutetium-177, immunotherapy, antibody therapy, syngeneic tumor model
- in
- Cancer Biotherapy & Radiopharmaceuticals
- volume
- 27
- issue
- 3
- pages
- 175 - 182
- publisher
- Mary Ann Liebert, Inc.
- external identifiers
-
- wos:000302573700001
- pmid:22417248
- scopus:84859609657
- pmid:22417248
- ISSN
- 1557-8852
- DOI
- 10.1089/cbr.2011.1132
- language
- English
- LU publication?
- yes
- id
- 1de6f07c-e471-4b1b-948a-b90fdd30ffc1 (old id 2431847)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/22417248?dopt=Abstract
- date added to LUP
- 2016-04-01 14:10:14
- date last changed
- 2022-04-22 01:45:05
@article{1de6f07c-e471-4b1b-948a-b90fdd30ffc1, abstract = {{Metastatic disease after successful treatment of the primary tumor continues to be a therapeutic challenge. Enhancement of therapeutic effects by the administration of unlabeled monoclonal antibodies (mAbs) after radioimmunotherapy (RIT) may provide a means of preventing or delaying the development of metastatic disease. In the present study, Brown Norway rats with syngeneic grafted colon carcinomas were administered the minimal effective therapeutic dose of 400 MBq/kg lutetium-177 ((177)Lu)-DOTA-BR96. After 2 weeks, half of the animals were given 15 mg/kg unlabeled mAb BR96 as consolidation therapy. Treatment response and toxicity were monitored 100 days after the treatment with unlabeled BR96. The treatment with unlabeled mAb after RIT resulted in a complete response (CR) in 19 of 19 animals, while RIT alone resulted in a CR in 17 of 19 animals. The additional treatment did not affect the number of animals with metastatic disease or the time to clinical symptoms of metastases. RIT resulted in reversible myelotoxicity. The unlabeled mAb BR96 did not cause any additional toxicity, making it possible to repeat the consolidation therapy.}}, author = {{Eriksson, Sophie and Ohlsson, Tomas G and Nilsson, Rune and Tennvall, Jan}}, issn = {{1557-8852}}, keywords = {{colon carcinoma; radioimmunotherapy; lutetium-177; immunotherapy; antibody therapy; syngeneic tumor model}}, language = {{eng}}, number = {{3}}, pages = {{175--182}}, publisher = {{Mary Ann Liebert, Inc.}}, series = {{Cancer Biotherapy & Radiopharmaceuticals}}, title = {{Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.}}, url = {{https://lup.lub.lu.se/search/files/3825709/2860363.pdf}}, doi = {{10.1089/cbr.2011.1132}}, volume = {{27}}, year = {{2012}}, }